Inhibrx Biosciences, Inc.
INBX
$113.73
$0.870.77%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 133.34M | 161.66M | 124.22M | 153.09M | 186.57M |
| Total Receivables | 132.00K | 186.00K | 177.00K | 837.00K | 967.00K |
| Inventory | 1.22M | 1.56M | 1.88M | 2.25M | 2.48M |
| Prepaid Expenses | 5.91M | 6.30M | 5.01M | 3.55M | 2.45M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 1.62M | 1.65M | 1.54M | 1.70M | 1.50M |
| Total Current Assets | 142.21M | 171.34M | 132.83M | 161.42M | 193.96M |
|
|
|||||
| Total Current Assets | 142.21M | 171.34M | 132.83M | 161.42M | 193.96M |
| Net Property, Plant & Equipment | 7.24M | 8.25M | 9.27M | 10.31M | 11.35M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 4.77M | 4.38M | 4.38M | 5.74M | 6.81M |
| Total Assets | 154.22M | 183.97M | 146.48M | 177.47M | 212.12M |
|
|
|||||
| Total Accounts Payable | 11.86M | 10.90M | 11.49M | 12.69M | 16.73M |
| Total Accrued Expenses | 13.71M | 13.20M | 19.99M | 21.05M | 20.04M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 2.49M | 2.41M | 2.33M | 2.25M | 2.17M |
| Total Finance Division Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Current Liabilities | 28.06M | 26.51M | 33.80M | 35.98M | 38.94M |
|
|
|||||
| Total Current Liabilities | 28.06M | 26.51M | 33.80M | 35.98M | 38.94M |
| Long-Term Debt | 176.29M | 174.99M | 100.56M | 99.92M | 99.28M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 2.85M | 3.50M | 4.13M | 4.74M | 5.34M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 207.20M | 205.00M | 138.49M | 140.64M | 143.56M |
|
|
|||||
| Common Stock & APIC | 263.30M | 258.59M | 254.18M | 250.18M | 246.66M |
| Retained Earnings | -316.28M | -279.63M | -246.19M | -213.35M | -178.10M |
| Treasury Stock & Other | -- | -- | -- | -- | -- |
| Total Common Equity | -52.98M | -21.04M | 7.99M | 36.83M | 68.56M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | -52.98M | -21.04M | 7.99M | 36.83M | 68.56M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | -52.98M | -21.04M | 7.99M | 36.83M | 68.56M |
|
|
|||||